The performance of six recently introduced highly sensitive enzyme-linked immunosorbent (ELISA) urine pregnancy test reagent kits was evaluated for false positive results using 100 male and 100 postmenopausal female urine specimens and the findings were compared with those of a qualitative radioimmunoassay (RIA) procedure. Based on the findings, the most suitable pregnancy test reagent kit was then selected for doing routine pregnancy testing of urine samples of premenopausal patients. The less sensitive PregnaSTICK® ELISA method and Concept 
THE LARGE NUMBER of various commercially available pregnancy tests raises the questions "If I have just one test to keep constantly available, which one should it be?" and "How sensitive does the routine test have to be?"
Because of rapid developments in immunochemical technics, the sensitivity of routine pregnancy tests has greatly increased. The new technology allows the detection of pregnancies about 9 days after ovulation or 23-25 days after the last menstrual period (LMP). Today pregnancy tests are performed not only for the detection of normal pregnancies after the first missed period but also for those women in the reproductive years who are at risk of being pregnant (i.e., having extensive x-ray procedures, being treated by certain medications, having elective curettage, ; to evaluate threatened, incomplete, or complete abortions; and to detect ectopic pregnancies before they rupture.
The circumstances described above indicate that, if the laboratory provides only one type of pregnancy test for routine use, then it should be the most sensitive test available without loss of specificity. After appropriate dilution of the specimens, these highly sensitive tests might also be used to estimate higher human chorionic gonadotropin (hCG) concentrations for confirming normal pregnancy or for evaluation of the "discriminatory zone" (6,000-6,500 mlU/mL [IU/L], first International Reference Preparation)* for the diagnosis of ectopic pregnancy. 14 However, the new highly sensitive pregnancy tests have to be evaluated extensively for false positives partly because the higher sensitivity leads to an inherent decrease in specificity 7 and partly because the new methods are based on new mechanisms. As the highly sensitive quantitative hCG methods have become more and more widely used, a number of reports have appeared in the literature about "discordant" or "aberrant" results of beta-hCG assays The use of specimens from young men and from postmenopausal females facilitates the screening for interference by a wide variety of diseases and other conditions and, at the same time* simplifies the interpretation of results because "subclinical pregnancies" of premenopausal women," 16, 22 ' 23 some of which may not be possible to 237 document, are excluded. We have applied such an approach earlier to adjust the sensitivity of a qualitative radioimmunoassay (RIA) hCG method to avoid false positive results. 2 During the following three years, the routine use of the adjusted RIA pregnancy test for testing specimens from women of childbearing years indicated that the experimental design and the selection of urine specimens appeared to be valid for effective screening of pregnancy test methods to avoid false positive results.
Recently, serum may have been the preferred specimen for pregnancy testing partly because it is more readily available in clinical emergencies and partly because the relationship between serum and urine hCG concentrations has not been widely known. It has also been assumed that sensitive tests could not be done with urine samples. 7 Several reports indicate, however, that especially in the first morning concentrated urine the hCG concentration may be higher than in the serum. Because nonspecific protein interference is less in the urine than in serum, hCG can perhaps be detected earlier in urine than in serum. 20, 21, 32 Objectives of this study were to evaluate the performance of recently introduced ELISA hCG methods to enable us to select one that had the lowest positive cutoff value (highest sensitivity) and the shortest turnaround time without false positive results (highest clinical specificity) for use in our laboratories. Urine samples from male patients were used to study the effects of uncertainty and variability in interpretation of negative assay results and to estimate the effects of various drugs. Urine samples from postmenopausal women were used to evaluate the effects of pituitary hormones, drugs, and possible contamination of urine samples with glycoproteins from vaginal secretions.
Materials and Methods
Pregnancy test reagent kits for qualitative and semiquantitative determination of beta-hCG (free beta chains or intact hCG) in urine were obtained from the following manufacturers: Nimbus® from NMS Pharmaceuticals, Inc., Newport Beach, California 92663; Tandem Icon HCG® (urine) from Hybritech, Inc., San Diego, California 92121; Testpack® (urine) from Abbott Laboratories, Chicago, Illinois 60064; Sensi-Chrome from Roche Diagnostic Systems, Nutley, New Jersey 07110; Pregna-STICK®, (urine) from Monoclonal Antibodies, Inc., Mountain View, California 94043; and Quest® from Quidel, La Jolla, California 92037. Concept® from Leeco Diagnostics, Inc., Southfield, Michigan, was also evaluated because this was the routine assay in our laboratory during this study.
The Nimbus, Icon, Testpack, Sensi-Chrome, Pregna-STICK, and Quest pregnancy tests are solid phase immunoenzymatic methods based on modified "sandwich" technics. Concept is a qualitative RIA.
Some of the reagent kits were calibrated against the World Health Organization (WHO) Second International Standard for hCG (second International Standard) and some were calibrated against the WHO First International Preparation for hCG (first IRP) (see Table 2 ). There is approximately a twofold difference in potency between the two international standards, but the difference is not linear throughout the concentration range because of differences in purity of standards and specificity of antibodies. 19, 26 If a kit calibrated against the second IS would report about 100 mlU/mL (IU/L) for a given sample, then another kit calibrated against the first IRP might report 200 mlU/mL (IU/L) hCG for the same sample. If the manufacturers of two pregnancy tests claimed the same sensitivities (smallest amount of detectable hCG), then, depending on the specificity of the antibodies, the reagent calibrated against the first IRP could be about two times more sensitive than the reagent calibrated against the second IS.
Fresh urine samples were obtained from the routine Urinalysis Laboratory of the Clinical Chemistry Division. Urine samples from 100 male (ages 5-40) and 100 postmenopausal female (age > 55) hospital laboratory specimens were selected from those samples that were sent to the laboratory for routine urine analysis and not for pregnancy testing.
The assays were run according to the manufacturer's instructions. During and immediately after the study, close contact was maintained with the manufacturers of the reagent kits. The results of the study were sent to each manufacturer, and positive urine samples were offered to provide the manufacturers the opportunity to test them and to confirm or to refute our results.
To minimize the effects of technologist's subjectivity, the results of each potentially ambiguous test that gave only questionable or slightly positive findings were interpreted by two technologists. If the second technologist was also uncertain about the result or found the result to be negative or doubtful, then the result was registered as negative. If the second technologist would have found the result to be positive, then the result would have been registered as indeterminate; this experience did not occur.
With the exception of the Testpack, the performances of all the reagents were compared by using identical urine samples to test each reagent. The Testpack, which became available only after the first part of this study was completed, was evaluated using a new set of urine samples. Those urine samples that gave positive results with Testpack were also analyzed with the Icon reagents but not with the other kits.
Comparison of Analytic Sensitivities
A urine sample from a pregnant patient was diluted with an hCG-negative male urine to obtain a urine sample having an hCG concentration of 100 mlU/mL (IU/L) (second IS). The Concept qualitative RIA method was used to estimate the hCG concentration of the diluted sample. The 100 mlU/mL (IU/L) hCG urine sample was then further diluted with the hCG-negative male urine to obtain urine samples having 10, 15,20, 25, 30,40, 50, or 60 mlU/mL (IU/L) hCG (second IS) concentrations, respectively. Each of these urine samples were then analyzed by all the investigated pregnancy test reagents, and the results were interpreted according to the instructions of the respective manufacturers.
The hospital medical record (chart) of patients whose urine samples gave positive pregnancy test results, except by Sensi-Chrome, were examined for relevant information, including clinical diagnoses, presence or absence of malignancies, and drug treatment. Table 1 shows some of the urine pregnancy tests that were commercially available in January 1986. A more complete list of the pregnancy tests, including the address of manufacturers and sensitivity and technology of the methods, is available upon request.
Results and Discussion
From these reagent kits, we selected six recently introduced ELISA methods for potential use in our laboratories (Table 2) . These pregnancy tests were described as the most sensitive and requiring the shortest technologist time. In June 1985, the costs, without any discounts, of the reagents of Nimbus, Quest, Sensi-Chrome, PregnaSTICK, and Concept assays per test were $1.40, $2.40, $1.99, $ 1.90, and $0.60, respectively. The costs, without any discounts, of Icon and Testpack per test were $2.75 and $6.00, respectively, in April 1986. The reagent cost of the ICON assay could be lowered by using the same reagent cup first for the negative control and then for the positive control. The price of those kits that were sold in local pharmacies for home use varied from $6.00 to $9.00 per test. The fee of a routine pregnancy test offered by commercial clinical laboratories varied from $7.00 to $18.00. Table 2 compares the performance characteristics of the selected reagents, and it shows that the analytic sensitivities claimed by the manufacturers of Nimbus, SensiChrome, and Concept were close to the analytic sensitivities observed in our laboratory. The observed sensitivity of Quest (15 mlU The Concept qualitative RIA pregnancy test has been used in our laboratories for a number of years for both urine and serum pregnancy tests. In 1983, we evaluated the performance of this test and we found that at sensitivity of 100 mlU/mL (IU/L) (second IS) it gave clinically validated false positive results with urine samples from premenopausal women. 10 Further studies showed that, among 100 postmenopausal female (age > 50) urine specimens, there were 4 with false positive results (apparent hCG was between 100 and 200 mlU/mL [IU/L], second IS). Leeco Diagnostics, Inc., confirmed the positive results on the postmenopausal urine samples. They apparently improved the specificity of the Concept antibodies, because during the present study the Concept reagents gave only negative results. 2 Among ELISA pregnancy tests that we selected for evaluation, the PregnaSTICK had the highest hCG "cutoff" concentration-175 mlU/mL (IU/L) (second IS). This reagent kit did not give any positive results.
The other five more sensitive (10-50 mlU/mL [IU/L], second IS) ELISA pregnancy tests could be placed into two groups, depending on whether the assay had built-in negative (and positive) control(s) or not. The Icon and Testpack permeable membrane and the Quest dipstick have, adjacent to the reactive area, an area that serves as a reference negative control. Presumably, the "negative area" does not contain any (or less) antibodies to bind hCG, and it serves as an internal control to monitor the effectiveness of the wash step. The residual nonspecifically bound antibody-linked enzyme, which was not washed off successfully, generates some color in both the reactive and the negative reference areas. The nonspecific color, however, is deducted from the color that is formed by hCG-bound antibody-linked enzyme when the color intensities of the two areas are compared; for a positive result, the reactive area must be darker than the negative area. If a highly intense color develops in the negative area, then the wash step was totally inadequate and the test has to be repeated. The negative reference area significantly contributed to the specificity of the assays, and it is probably not a coincidence that, in our hands, the three products that have negative reference areas (Testpack, Icon, and Quest) gave significantly fewer false positive results than the other two products (Nimbus and Sensi-Chrome).
A high correlation existed between the Nimbus, SensiChrome, and Quidel® positive results. All the Nimbuspositive male urine samples also gave positive results with Sensi-Chrome, and 88% of the Nimbus-positive female urine samples were also positive with Sensi-Chrome. Among the Quidel-positive samples, there was only one male and one female urine sample that was not positive by both of the other two methods.
NMS Pharmaceuticals, Inc., confirmed some of the Nimbus-positive results and found the hCG level to range from 4 to 15 mlU/mL (IU/L) (second IS) by a quantitative hCG method.
All the ELISA pregnancy tests were difficult to interpret if the concentration of hCG was near the sensitivity of the assay. To increase the accuracy of our study, two technologists interpreted every ambiguous result (see "Materials and Methods"). In case of the Sensi-Chrome kit, the interpretation ofresults were especially difficult. Peele and Russel also evaluated the Roche Sensi-Chrome reagent, and their observations were not unlike those that are reported here. 23 Among the first set of 200 urine samples, we did not find any false positives with the Icon. Among the second 200 urine samples, we found one positive and a weak positive postmenopausal female urine sample by Testpack. The Icon reagents gave positive results with both of these samples. Abbott Laboratories confirmed these observations with both the Testpack and Icon reagents and estimated the hCG concentration to be about 50 mlU/ mL (IU/L) (first IRP) in the more concentrated sample.
The built-in positive control of the Testpack reagents represent the latest significant development in the immunochemical methods of pregnancy testing. In our hands, the only undesirable characteristics of the Testpack was that the color continued to develop even after the color reagents were removed by washing. According to the manufacturer's instructions, the results should be interpreted 2 minutes after the addition of the color reagents because "a full 2 minutes color development is required for maximum sensitivity or to confirm negative results." The instability of Testpack color after the 2 minutes made it necessary to interpret the results exactly at 2 minutes because low-titer hCG samples gave different results at 2 minutes and at about 5 minutes after the addition (and removal) of the color reagents. To estimate the relative sensitivities of ICON and TESTPACK reagents, we prepared several urine samples by serial dilution (with hCGnegative male urine) of a pregnant female urine specimen. The 8,000-fold diluted sample was negative with ICON, but the 4,000-and 2,000-fold diluted samples were positive. Two minutes after addition, the color reagents of Testpack were removed by washing and the results were interpreted: the 2,000-and 4,000-fold diluted urine samples were positive, but the 8,000-fold diluted sample was negative. After an additional 5 minutes, the same Testpack reagents were reinterpreted, and all three samples were found to be positive. In contrast, the color of the ICON reagents is stable for several hours-several days if they are kept in a freezer covered with parafilm. We have tested some samples of a new version of the Icon that has built-in positive control and found them functioning well.
The medical records of 24 patients whose urine sample gave positive results with Nimbus and/or Quest assays were examined for information that would have explained the positive results. A specimen from a 21-year-old male patient under treatment for a known hCG-secreting embryonal carcinoma of the testes with metastases was positive with all the kits studied. This patient was excluded from the data presented in Table 2 . The medical records of the other 23 patients did not reveal any clear-cut information to explain the positive hCG results. There were four patients with carcinoma (breast, colon, and lung), one patient with myeloma, and one patient who had a small bowel infarct and was autopsied with no unexpected findings. The rest of the patients were treated for diabetes (three), hypertension (two), psychologic disorders (four), acute pancreatitis (one), other infections, and stab wounds. Review of these charts and others with negative findings, especially for medications and other laboratory data, revealed no well-defined clues except for the microscopic urinalysis. This showed that the mucus content of female, but not that of male, urine samples correlated with the incidence of false positive hCG. The data in Table 3 show that a higher percentage of the false positive urine samples contained mucus (76%, 75%, or 57%) than of the hCG negative samples (28%, 35%, or 26%). Furthermore, this correlation existed for all the hCG reagents tested with the first 200 urine samples. The nature of this finding is under further study. Other urinalysis data showed no discernible correlation.
The medical records of the two postmenopausal female patients whose urine samples gave positive results with Testpack and Icon reagents did not reveal information that would suggest the presence of trophoblast or other hCG secreting tissues. One of the patients, a 63-year-old female, whose apparent urine hCG was higher (~ 50 mlU/ mL [IU/L] first IRP), had chronic obstructive pulmonary disease, acute bronchospasm, bronchitis, asthma, nasal polyps, and traumatic arthritis of the knees. Sputum cytologic examination showed acute inflammation with rare atypical epithelial cells. Medications included theophylline and steroids. The other patient, a 59-year-old female, had a squamous cell carcinoma of the larynx, total laryngectomy eight years ago, followed by postradiation stricture of the esophagus, esophagectomy, and stomach biopsies. However, there is currently no tissue or clinical evidence for any residual or recurrent tumor since laryngectomy.
The exact causes of the apparently false positive pregnancy test findings reported in this communication are not known. To interpret these results one needs to distinguish the potentially "discordant" or "aberrant" results possibly resulting from "normal" low levels of hCG from those that are "false positive" caused by random errors or by non-hCG materials. The importance of thorough evaluation of pregnancy test reagents for false positive findings is underlined by the fact that at this time there are no practical and effective methods for differentiating low-titer "aberrant" or false positive hCG results from early pregnancy during routine pregnancy testing.
Discordant hCG results are classified as those that seem to be inconsistent with the clinical status of the patient. Usually a low positive result occurs (5-40 mlU/mL [IU/ L]), although there is no evidence of pregnancy, trophoblastic disease, or malignancy. The sequential hCG titer does not change with time, and the same sample may give negative results with alternative procedures. The data reported by Braunstein and co-workers 4 showed that 2.6% of 2,690 nonpregnant patients, none of whom had neoplasms, had hCG-positive sera in the range of 5-25 mlU/ mL (IU/L) (second IS). Because a number of clinical conditions are associated with very low levels of hCG, there is a danger in defining a "normal limit" of hCG for nonpregnant patients, below which the results cannot reliably be interpreted. Solutions to these problems have been recommended, 13 and the use of highly sensitive pregnancy tests needs to be continued.
Low circulating hCG concentrations occurring in some normal nonpregnant humans 1 ' 4 ' 6,29 have been found to be associated with women using intrauterine contraceptive devices (IUDs), 3 '"' 16 ' 22,33 with the occurrence of low-carbohydrate-containing physiologically inactive but immunologically active hCG, 34 and with the occurrence of free beta subunits or segments of the beta chain produced by tumor cells. 51015 Discordant pregnancy test results, caused by free beta chains of hCG, can be avoided by use of reagents that are specific for the intact hCG molecule, such as the Icon and Testpack.
Low false positive results could be caused by cross-reaction by high concentrations of hLH, especially at low hCG levels (25- 27 by reactions of the patient's antigoat or antibovine heterophil antibodies with the hCG antibodies, 31 by some drugs or their metabolites, 24 by some pathologic metabolites of an ill patient, or by random variability in the interpretation of an assay that has a subjective endpoint. 23 Enzyme linked assays may yield spurious "hormone" concentrations because some components in the patients' sample may interact nonspecifically with the enzyme linked to the antibody to induce a non-endocrinerelated response. 29 Among the 52 and 21 positive results that were obtained with the Sensi-Chrome and Nimbus reagents, respectively, there were probably some that were caused by random error in differentiating the negative and apparently lowtiter positive results. The rest of the positive results found by Sensi-Chrome, Nimbus, and Quest probably were caused by some unknown but common interference, because high correlation was found among the positive results. It is highly unlikely that the hCG concentration of these samples was higher than what has been reported in serum of apparently normal nonpregnant humans, 15 mlU/mL (IU/L) (second IS), because (1) the Icon, one of the most sensitive reagents, gave negative results with these samples; (2) by a quantitative method, NMS Pharmaceuticals did not find any samples with higher hCG concentrations (see Table 2 ); and (3) the medical history of these patients did not reveal any clear reasons for the positive results. Only the mucus content of the urine showed correlation with the positive findings.
In contrast, those samples of the second set of 100 postmenopausal female urine samples, which were found positive by the Testpack, were confirmed by Icon in our and in the Abbott Laboratories. They seem to contain hCG or some hCG-like material because the presence of hCG was confirmed by two independent sensitive arid specific tests. The clinical history of these patients does not, at this time, support the presence of hCG-secreting tissues, but we continue monitoring their medical progress.
If the apparent lack of specificity evidenced by the false positive hCG results detected in this study is an acceptable index of the reliability of urine pregnancy tests, then it seems that the Testpack (Abbott) or the Tandem Icon HCG (Hybritech) may be the methods of choice, especially for an emergency room setting. These tests require only 6 minutes of technologist time, and they gave the least number of apparently false positive results in this study. The combined high clinical specificity (lack of false positives) and high analytic sensitivity of the Testpack and Icon could result, at least in part, from the specificity of the antibodies to intact hCG, as opposed to any type of hCG beta chain, and to the presence of the "internal negative control," which very likely contributes to low random errors in the interpretation of negative and low positive results. The positive control of the Testpack and that of the newer Icon could be valuable in avoiding false negative results caused by faulty technics or defective reagents; the very same reagents that are used for the unknown assay are also used simultaneously for quality control.
